The estimated Net Worth of Mathai Mammen is at least $4.49 Million dollars as of 11 May 2023. Mathai Mammen owns over 200,000 units of 10x Genomics stock worth over $4,480,665 and over the last 10 years he sold TXG stock worth over $0. In addition, he makes $13,696 as Independent Director at 10x Genomics.
Mathai has made over 3 trades of the 10x Genomics stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 200,000 units of TXG stock worth $232,000 on 11 May 2023.
The largest trade he's ever made was exercising 200,000 units of 10x Genomics stock on 11 May 2023 worth over $232,000. On average, Mathai trades about 11,324 units every 24 days since 2014. As of 11 May 2023 he still owns at least 202,745 units of 10x Genomics stock.
You can see the complete history of Mathai Mammen stock trades at the bottom of the page.
Dr. Mathai Mammen M.D. Ph.D. serves as Independent Director of the Company. He has served on our board of directors since August 2017. Dr. Mammen currently serves as global head, research and development at the Janssen Pharmaceutical Companies of Johnson & Johnson. Prior to joining Janssen Pharmaceutical Companies in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories from March 2016 to June 2017. Prior to Merck, Dr. Mammen led research and development at Theravance, a company he co-founded in 1997 until March 2016. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva and Theravance Biopharma. Dr. Mammen received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry. He received his B.Sc. in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.
As the Independent Director of 10x Genomics, the total compensation of Mathai Mammen at 10x Genomics is $13,696. There are 13 executives at 10x Genomics getting paid more, with Serge Saxonov having the highest compensation of $2,362,960.
Mathai Mammen is 52, he's been the Independent Director of 10x Genomics since 2017. There are 7 older and 9 younger executives at 10x Genomics. The oldest executive at 10x Genomics, Inc. is John Stuelpnagel, 62, who is the Independent Chairman of the Board.
Mathai's mailing address filed with the SEC is C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON, CA, 94588.
Over the last 5 years, insiders at 10x Genomics have traded over $629,686,183 worth of 10x Genomics stock and bought 487,816 units worth $19,025,295 . The most active insiders traders include Bryan E Roberts, Capital Management I, Llc F..., and Benjamin J. Hindson. On average, 10x Genomics executives and independent directors trade stock every 8 days with the average trade being worth of $1,002,346. The most recent stock trade was executed by Serge Saxonov on 22 August 2024, trading 6,749 units of TXG stock currently worth $152,055.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
10x Genomics executives and other stock owners filed with the SEC include: